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ABSTRACT
Wnt10b is a canonical Wnt ligand expressed in developing bone and has been linked to mesenchymal progenitor functions in mice and
humans. Because Wnt signaling has been shown to play an important role in progenitor maintenance in a variety of adult tissues, we
examined bone deposition and growth rates throughout postnatal development in Wnt10b-null mice. Using bone histomorphometry
and micro–computed tomographic (mCT) studies, we demonstrate that trabecular bone deposition is slightly enhanced in Wnt10b-null
mice at 1 month of age, followed by progressive loss with age. Importantly, we find that Wnt10b is required for maintenance of adult
bone density in multiple backgrounds of inbred mice and that both copies of the Wnt10b gene are required to maintain normal bone
density in 6-month-old animals. We go on to show that the loss in trabecular bone inWnt10b-null mice is associated with a reduction in
the number of bone marrow–derived mesenchymal progenitors (MPCs) using in vitro colony-forming unit assays and marker analysis.
Analysis of osteogenic gene expression in primary bone marrow stromal cells demonstrated reductions in expression of several
osteoblast differentiation markers. Taken together, our results indicate that Wnt10b is uniquely required for maintenance of
mesenchymal progenitor activity in adult bone. The results show the significance of studying individual Wnt ligands and their
potentially unique contribution in the context of aging and disease.  2010 American Society for Bone and Mineral Research.
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During embryonic development, mesenchymal progenitorcells (MPCs) contribute to the various derivatives of
mesenchyme, including bone, fat, muscle, and cartilage. In
adults, cells with MPC-like characteristics are present in most
tissues and may contribute to remodeling and repair of
mesenchymal derivatives.(1,2) Wnt signaling has been implicated
in various aspects of mesenchymal development,(3) including
suggested roles in the maintenance, proliferation, and differ-
entiation of postembryonic bone(4–6) and in establishment and
maintenance of adult mesenchymal stem cells.(7) Misregulation
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2138in other disorders of mesenchymal origin. While not excluding
other mesenchymal derivatives, activation of Wnt signaling
generally is associated with expansion of the osteoblast and
chondrocyte lineages in vivo and in vitro,(3,9–12) and canonical
Wnt ligands lead to expansion of MPCs at the expense of
differentiation in vitro.(13,14)
Wnt genes encode a family of conserved extracellular growth
factors, with 19 members in mammals. Most Wnt proteins are
thought to act as ligands for cell surface receptor complexes
composed of frizzled (Fz) and low-density lipoprotein (LDL)–
receptor–related protein 5/6 (LRP5/6) family members. Down-
stream of Fz-LRP5/6 complexes, canonical Wnt signaling results
in stabilization and translocation of b-catenin to the nucleus,ted April 15, 2010. Published online April 30, 2010.
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where it binds to T-cell factor/lymphoid enhancer factor (TCF)/
Lef transcription factors. b-Catenin–TCF/Lef complexes activate
transcription of a variety of Wnt-responsive genes, including
genes involved in proliferation and osteoblastogenesis.(15)
Wnt10b is expressed in the bone marrow, postnatal growth
plate,(16) osteoblastic precursors,(17) and various other stem cell
compartments. It has been shown to activate transcription of
canonical Wnt targets, including Id2 and cyclin D1.(18,19) Previous
work has shown that transgenic overexpression of Wnt10b in
mesenchymal derivatives leads to increased bone density,
increased trabecular number and thickness in vivo, and accelerated
osteoblastogenesis in vitro.(19,20) This work also demonstrated that
Wnt10b-null mice have reduced trabecular mass at 8 weeks;
however, a full characterization of the observed phenotype was
not undertaken.
To elucidate cellular defects contributing to low adult bone
mass in Wnt10b-null mice, we examined bone deposition and
growth rates throughout postnatal development. We found that
Wnt10b-null mice display a progressive loss of trabecular
structure and went on to identify a pronounced trabecular
phenotype in Wnt10b heterozygous mice. Interestingly, we
found that Wnt10b-null animals showed enhanced trabecular
structure at 2 and 4 weeks of age but that the increase was
rapidly followed by progressive osteopenia from 2 to 6 months
of age. These results lead us to hypothesize that Wnt10b
expression helps to maintain osteoblast progenitors in an
undifferentiated state and that loss of Wnt10b expression results
in either increased differentiation or decreased self-renewal of
mesenchymal progenitors. The result of decreased Wnt10b
expression thus could lead to early exhaustion of the progenitor
pool and subsequent loss of bonemass with age. Consistent with
this hypothesis, we find that the age-progressive osteopenia is
associated with decreased recovery and activity of mesenchymal
progenitors from bone marrow. Specifically, the loss of Wnt10b
resulted in decreased recovery of mesenchymal progenitor cells
(MPCs) and MPC lineage–derived osteoblastic activity as assayed
by in vitro colony-forming unit (CFU) assays andmarker analyses.
Taken together, these results suggest that Wnt10b is a key
regulator of the mesenchymal progenitor fate and that it is
required late in life for maintenance of postnatal osteogenic
progenitors.
Materials and Methods
Generation and genotyping of Wnt10b-null mice
A null allele (Wnt10bDex2-5) was generated through homo-
logous recombination by introducing the neomycin resistance
gene in lieu of the endogenous exons 2 to 5 of the mouse
Wnt10b gene, including most of intron 4 and part of exon 5. The
Wnt10bDex2-5 targeting vector (Fig. 1A) was created from 129SvEv
genomic fragments cloned into the pPNT targeting vector.(21)
The vector then was electroporated into TC-1 embryonic stem
cells,(22) and colonies were selected by growth on embryonic
fibroblasts in medium supplemented with LIF-1, G418, and FIAU.
Three properly targeted colonies were identified by Southern
blot analysis and used to generate chimeric founder animals.
Founders were backcrossed into FVB/N or C57Bl6 for 12MAINTENANCE OF MESENCHYMAL PROGENITORS BY WNT10Bgenerations to create Wnt10bD2-5FVB and Wnt10bDex2-5Bl6, respec-
tively. Genotyping of F1 through F9 animals was performed by
genomic Southern blot, and PCR was used thereafter. Genomic
DNA was prepared from tail-snip biopsies following standard
protocols. Southern blot analysis was carried out on Sal1-Cla1
digested DNA, and blots were probed with 5’ genomic fragment
(Fig. 1A) not included in the original targeting vector. Once lines
were established, they were monitored by PCR using a
combination of neospecific and exon 5–specific primers. PCR
conditions and primer sequences can be found in Supplemental
Table 1 and Supplemental Materials and Methods. Except for Fig. 3
and one panel of Fig. 5, all studies presented in this article were
completed using mice in the FVB background.
Quantitative RT-PCR
Total RNA was extracted from plastic-adherent primary bone
marrow–derived stromal cells and passage 2 calvarial osteoblasts
using TRIzol (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s instructions. RNA was DNaseI treated and cDNA
generated with the iScript cDNA Synthesis Kit (BioRad, Hercules,
CA, USA) following the manufacturer’s instructions. Quantitative
RT-PCR was performed on cDNA using the Power SYBR Green
amplification system (Applied Biosystems, Carlsbad, CA, USA)
following the manufacturer’s instructions. PCR conditions and
primer sequences can be found in Supplemental Table 2 and
Supplemental Materials and Methods.
Histomorphometry and micro–computed tomography
(mCT)
One-, two-, three-, and six-month-old wild-type (WT) and
Wnt10b-null male mice were given single intraperitoneal
injections of 20mg of calcein (C0875, Sigma Aldrich, St. Louis,
MO, USA) per kilogram of body weight on day 1 and 20mg of
demeclocycline (D6140, Sigma Aldrich) per kilogram of body
weight on day 3 (1 month), day 6 (2 months), or day 8 (3 and 6
months). Mice were euthanized 2 days following final injection.
Femurs from each mouse were dissected free of tissue, fixed in
70% ethanol, and embedded in methyl methacrylate (right
femur) or prepared for analysis by mCT (left femur). For
histomorphometry, 5-mm-thick longitudinal sections were cut
through the trabecular region of the distal femur and toluidine
blue stained for analysis using image analysis software
(Osteomeasure, Atlanta, GA, USA). Osteoblast and osteoclast
numbers were measured, and the mineral apposition rate (MAR)
and mineralizing surface/bone surface (MS/BS) were calculated
as described previously.(23) For mCT, the left distal femur from 6-
month-old male C57/Bl6 mice was scanned at 6-mm resolution.
Images were generated using the 3D visualization/animation
component of the SkyScan 1172 X-ray microtomograph and CT
analyzer software (Kontich, Belgium).
Primary bone marrow stromal cell isolation, osteo/
adipogenic differentiation, and histologic staining
Tibias and femurs of WT and Wnt10b-null mice at 6 months of
age were flushed with complete growth media (DMEM supple-
mented with 10% FBS; Omega Scientific, Tarzana, CA, USA), 5%
L-glutamine, and 5% penicillin-streptomycin (CellGro, Lawrence,Journal of Bone and Mineral Research 2139
Fig. 1. Wnt10b-null mice appear morphologically normal and have normal growth rates. (A) The design of theWnt10bDex2-5 targeting vector is illustrated.
The targeting vector completely eliminates the coding region between exon 2 and the Cla-1 site in exon 5. The construct was transfected intomouse ESTC1
cells, and cloneswere selected for homologous recombination. Three targeted cloneswere identified showing the expected integrationwithin theWnt10b
locus. (B) Southern blot analysis of genomic DNA isolated from wild-type (WT), heterozygous, and Wnt10b-null mice. DNA was obtained from a litter of
pups created from a cross betweenWnt10bDex2-5-heterozygous parents. DNAwas digestedwith both Sac-1 (S) and Cla-1 (C) and hybridizedwith a probe to
sequences 5’ to the construct (Probe). The expected 2.4-kb shift is observed. (C) Quantitative PCR analysis ofWnt10bmRNA expression in calvarial osteoblasts
and primary bone marrow stromal cells (PBMSCs) isolated from WT and Wnt10b-null mice. (D) Images of WT andWnt10b-null mice showing no difference in
overall gross morphology when examining either the exterior (i) or X-ray images of skeletal structures (ii). (E, F) Graph of growth rate for female (E) andmale (F)
WT (black box), heterozygous (blue diamond), and Wnt10b-null (red circle) mice. All experiments in this figure use mice in the FVB background.KS, USA) and passed through a 40-mm nylon mesh cell strainer
(Becton Dickinson, Franklin Lakes, NJ, USA) to make a single-cell
suspension. Total bone marrow was suspended in complete
medium (for osteogenesis) or Mesencult (for adipogenesis) at
2 106 nucleated cells per milliliter, seeded at 2 106 nucleated
cells per well in 12-well tissue culture plates, and incubated at
378C in 5% CO2 for 5 days. Nonadherent cells then were
removed, and adherent cells were washed, fed, and grown to
70% confluence in complete growth medium or Mesencult as
indicated, at which point cells were switched to osteogenic
medium (a-MEM supplemented with 10% FBS, 5% L-glutamine,
5% penicillin-streptomycin, and 2mM b-glycerophosphate;
G9891, Sigma Aldrich) and 50mg/mL of L-ascorbic acid
(A8960, Sigma Aldrich) or adipogenic medium (DMEM supple-
mented with 10% FBS, 5% L-glutamine, 5% penicillin-strepto-
mycin, and 1mM PPARg agonist GW1929). Medium was
replenished every third day until formation of osteogenic bone2140 Journal of Bone and Mineral Researchnodules (for osteogenesis assays) or formation of lipid droplets
(for adipogenesis assays) in control wells. Colonies then were
stained for alkaline phosphatase activity (86R, Sigma Aldrich)
following the manufacturer’s instructions and calcium deposi-
tion (nodulation) by incubation in 5% silver nitrate (S486, Fisher
Scientific, Waltham, MA, USA) solution under ultraviolet (UV) light
for 60minutes or stained with oil red O following standard
protocols. Nodulation was quantified as a direct count of the
number of ossification centers present, and adipogenesis was
assessed by enumeration of oil red Oþ colonies.
Enumeration and differentiation of mesenchymal stem
cells harvested in Mesencult
Primary bone marrow stromal cells were isolated as described
earlier. Total bone marrow was diluted in Mesencult basal
medium plus supplements (Stem Cell Technologies, Vancouver,STEVENS ET AL.
BC, Canada) and seeded at 5.0 105 nucleated cells per well of a
6-well plate. Cells weremaintained at 378C in 5% CO2 for 10 days.
Colonies were stainedwith Geimsa, and the colony-forming units
fibroblastic (CFU-F) were enumerated by counting. For osteo-
genic and/or adipogenic differentiation, cells were switched to
osteogenic or adipogenic medium (described earlier) at day 10,
with subsequent medium changes every third day until formation
of osteogenic nodules and/or formation of lipid droplets. The
plates then were stained and enumerated by counting positive
colonies.
Serology
Blood from 3- and 6-month-old WT and Wnt10b-null mice was
harvested at the time of euthanization, and serum was prepared.
Serum cross-linked C-telopeptide (CTx) was measured using
a RatLaps ELISA Kit (1RTL4000, Nordic Biosciences, Herlev,
Denmark) following the manufacturer’s instructions.
Results
Wnt10b-null mice appear morphologically normal and
have normal growth rates
Wnt10b-null mice were generated by homologous recombina-
tion, replacing exons 2 to 4 and a portion of exon 5 with a
neomycin resistance cassette (Fig. 1A). Deletion of the Wnt10bFig. 2. Wnt10b-null mice show increased bone accrual at young ages followed
methyl methacrylate sections were prepared from the distal femurs of 1-, 2
properties of distal femurs from 1- (n¼ 4), 2- (n¼ 8), 3- (n¼ 7), and 6-month-old (
analyzed for bone volume fraction (BV/TV%, B), trabeculae/mm (C), and trabecul
andWnt10b-null mice. (F, G) 3D mCT analysis of 1- (n¼ 5) and 4-week-old (n¼ 8)
(BV/TV%, F) and trabeculae/mm (G). All experiments in this figure usemice in the
ap< .05.
MAINTENANCE OF MESENCHYMAL PROGENITORS BY WNT10Blocus was validated by Southern blot analysis using a flanking
probe (Fig. 1B). Quantitative RT-PCR of primary bone marrow
stromal cells (PBMSCs) and calvarial osteoblasts demonstrates
expression ofWnt10bmRNA in these cells and confirms thatmice
homozygous for deletion of the Wnt10b locus do not express
Wnt10b mRNA (Fig. 1C). Outwardly, Wnt10b-null mice appear
normal (Fig. 1D, i) and have normal litter size, and similar growth,
as assessed by weekly weight measurements from birth to
4 months of age (Fig. 1E, F). Gross morphologic examination of
the skeletal structure of Wnt10b-null mice reveals no apparent
defects in either the length or width of the long bones (Fig. 1D, ii).
Wnt10b-null mice exhibit enhanced early maturation
followed by age-progressive loss of trabecular bone
(osteopenia)
Two-dimensional histomorphometry was carried out on the
distal femoral metaphyses from 1-, 2-, 3-, and 6-month-old WT
and Wnt10b-null mice backcrossed into the FVB background
(Fig. 2A). One-month-old Wnt10b-null mice have statistically
significant increases in bone volume fraction (BV/TV; Fig. 2B) and
trabecular number (Tb.N; Fig. 2C) with concurrent decreases in
trabecular spacing (Tb.Sp; Fig. 2D). WT mice show relatively little
difference in all structural parameters between 1 and 3 months
of age. At 6 months of age, WT mice show decreases in bone
volume fraction and trabecular number with concurrent increases
in trabecular spacing (Fig. 2B–D). In contrast, Wnt10b-null mice
show progressive reductions in trabecular mass as they mature,by an age-dependent loss of trabecular bone. (A) Toluidine blue–stained
-, 3-, and 6-month-old WT and Wnt10b-null mice. (B–D) Morphometric
n¼ 10) maleWT (black bar) andWnt10b-null (gray bar) mice. Femurs were
ar spacing (D). (E) mCT images of distal femurs from 2- and 4-week-old WT
male (black bar) andWnt10b-null (gray bar) mice for bone volume fraction
FVB background. Statistical significance was evaluated by Student’s t test;
Journal of Bone and Mineral Research 2141
Fig. 3. Wnt10b is also required for maintenance of bone density in the
C57/BL6 strain of mice, and loss of one allele is sufficient to generate
severe osteopenia by 6 months of age. (A) mCT images of distal femurs
from WT (i), Wnt10bþ/– (ii), and Wnt10b-null (iii) mice. (A–C) 3D mCT
analysis of 6-month-old WT (n¼ 4, black bar), Wnt10bþ/– (n¼ 4, white
bar), and Wnt10b-null (n¼ 4, black bar) mice for trabeculae/mm (B) and
bone volume fraction (BV/TV%, C). All experiments in this figure use mice
in the C57/Bl6 background. Statistical significance was evaluated by
Student’s t test; ap< .05.indicating a loss of the ability to maintain trabecular mass. At 2, 3,
and 6 months of age,Wnt10b-null mice show significant decreases
in both bone volume fraction (BV/TV; Fig. 2B) and trabecular
number (Fig. 2C) with concurrent increases in trabecular spacing
(Fig. 2D). Analysis of trabecular and cortical thickness revealed no
differences in these parameters at 1, 2, 3, or 6 months of age
(data not shown). These results were confirmed independently
by 3D mCT analyses (data not shown). Trabecular connectivity
(Conn.D) measurements are consistent with measurements of
trabecular number and spacing, showing no difference at 1 month
of age but an age-dependent decrease beginning at 2 months of
age (data not shown).
In order to further examine the interesting observation that
structural parameters are increased at 1 months of age inWnt10b-
null mice, we performed additional mCT analyses on 2- and 4-
week-old WT and Wnt10b-null mice (Fig. 2E). Wnt10b-null mice
show an approximately 1.5-fold increase in bone volume fraction
at 2 weeks and an approximately 1.2-fold increase at 4 weeks (BV/2142 Journal of Bone and Mineral ResearchTV; Fig. 2F). These increases in BV/TV are associated with an
increase in the number of trabeculae per millimeter (Fig. 2G) with
no alteration in trabecular thickness (Fig. 2G; data not shown).
Additionally, mCT analysis of femurs from WT andWnt10b-null
mice backcrossed into the C57/Bl6 background line (Fig. 3A–C)
also show a 50% decrease in bone volume fraction (BV/TV;
Fig. 3A, C) and a 50% decrease in trabeculae per millimeter
(Fig. 3A, B). In combination with the data presented in Fig. 1,
these data illustrate that the bone-loss phenotype is robust and
is present in at least two genetic backgrounds. Interestingly, this
analysis also showed that mice heterozygous for deletion of the
Wnt10b gene display a loss of trabecular bone at 6 months of age
(Fig. 3A, ii, B, C). We have not determined whether bone loss is
progressive in the C57 background, but these mice also grow at
normal rates and do not appear to be different from FVB mice
carrying the null allele.
Measurements of dynamic bone formation in FVB mice reveal
that the extent of mineralization in WT mice declines when rapid
growth ceases at 2 months of age, at which point it plateaus and
remains constant (MS/BS; Fig. 4A). This is in contrast to Wnt10b-
null mice, in which the percentage of bone undergoing active
mineralization is far below WT levels at 1 month of age. As a
percentage of surface area, mineralization of Wnt10b-null bone
becomes more similar to that of WT mice at 3 months of age but
subsequently drops back belowWT levels by 6months. Interestingly,
the matrix apposition rate (MAR), a measure of the rate of bone
formation, is equivalent in 1-, 2-, and 3-month-old animals, with
significant reductions in this parameter observed by 6 months of
age (MAR; Fig. 4B).
These data, along with the observation that bone volume
fraction and trabecular number are increased in Wnt10b mice at
2 and 4 weeks of age, suggest a role for Wnt10b in maintaining
bone-forming osteoprogenitor cells in an undifferentiated state.
The early increases in bone volume fraction and trabecular
number in 2- and 4-week-old mice could reflect an initial period
of accelerated differentiation of mesenchymal/osteoprogenitors
resulting in depletion of a pool of stem cells that are not
maintained over the life of the animal.
Age-progressive osteopenia in Wnt10b-null mice is not
due to abnormal bone resorption
Type I osteoporosis in humans typically is characterized by
excess bone resorption in the absence of increased bone
formation and occurs primarily in postmenopausal females when
estrogen levels decline. However, non-estrogen-dependent
osteoporosis phenotypes have been reported for both males
and females in humans. The observation that Wnt10b-null
animals have decreased bone volume by 2 months of age
suggests that Wnt10b-null animals represent a model of osteo-
porosis. Histomorphometric data shownodifference in osteoblast or
osteoclast number per trabecular bone area (Fig. 5A, B) nor an
increase in osteoclast activity, as assessed by analysis of serum CTx
levels (Fig. 5C). These results indicate that the age-progressive
osteopenia is not due to increased bone resorption but rather is the
result of decreased bone deposition. In accordance with this idea,
we observed reductions in percent mineralizing surface in 1-, 2-,
and 6-month-old animals (MS/BS; Fig. 4A).STEVENS ET AL.
Fig. 4. Dynamic properties of bone formation in WT and Wnt10b-null
mice. (A, B) Dynamic properties of bone formation for 1- (n¼ 4), 2- (n¼ 6),
3- (n¼ 5), and 6-month-old (n¼ 8) male WT (black bar) and Wnt10b-null
(gray bar) mice. Femurs were analyzed for mineralizing bone surface (MS/
BS%, A) and matrix apposition rate (mm/day, B). All experiments in this
figure use mice in the FVB background. Statistical significance was
evaluated by Student’s t test; ap< .05; bp< .01.
Fig. 5. The age-progressive osteopenia in Wnt10b-null mice is not due to
abnormal bone resorption but is associated with decreased numbers of
osteogenic and adipogenic progenitor cells in aged mice. Histomorpho-
metric analysis shows no significant difference in the number of osteoclasts
(A) or osteoblasts (B) at 1 (n¼ 4), 2 (n¼ 7), 3 (n¼ 7), and 6 (n¼ 7) months of
age. Analysis of serum CTx (C) in 3- (n¼ 3) and 6-month-old (n¼ 3) animals
shows no significant difference in osteoclast activity. (D) Dual alkaline
phosphatase/von Kossa stains of 3-week- and 6-month-old primary bone
marrow stromal cells (PBMSCs) induced to differentiate down the osteo-
blastic lineage show a reduction in the number of ossified centers in
Wnt10b-null PBMSCs at 6 months but no difference at 3 weeks. (E)Wnt10b-
null PBMSC (gray bar) shows a statistically significant decrease in the
number of centers compared with WT (black bar) at 6 months but not 3
weeks. (F) Wnt10b-null PBMSC (gray bar) shows a statistically significant
decrease in the number of adipogenic centers at 6 months compared with
WT (black bar). (G) Quantitative PCR analysis of mRNA isolated from WT
(black bar) and Wnt10b-null (gray bar) PBMSCs following 10-day expansion
in growth medium. Wnt10b-null PBMSCs from 6-month-old mice show
decreases in alkaline phosphatase (AP), osteocalcin (OCN), and Id2 expression
but no change in Runx2. All experiments in this figure were performed in
triplicate. Technical replicates from a representative biologic replicate are
shown. All experiments in this figure use mice in the FVB background, with
the exception of the CFU-A experiments, in which C57/Bl6 mice were used.
Statistical significance was evaluated by Student’s t test; ap< .05; bp< 01.Primary bone marrow stromal cells from Wnt10b-null
mice have fewer osteoprogenitors by 6 months of age
Previous work has suggested that overexpression of Wnt10b can
enhance bone deposition,(19,20) leading to the suggestion that
Wnt10b acts to promote differentiation. However, our data
suggest that Wnt10b is important to maintain mesenchymal/
osteoprogenitors and that loss of expression leads to premature
bonematuration, as evidenced by enhanced bone formation at 2
and 4 weeks of age that is accompanied by a subsequent
inability to maintain trabecular bone. To examine whether loss of
Wnt10b affects the number and function of osteoprogenitors, we
performed in vitro osteogenesis assays. Primary bone marrow
stromal cells (PBMSCs) containing both mesenchymal and
osteoprogenitor cells were isolated from 3-week- and 6-
month-old WT and Wnt10b-null mice. Isolated cells were
expanded for 10 days to remove most hematopoetic derivatives
and then induced to differentiate down the osteoblastic lineage
by growth in osteogenic medium (containing 50mg/mL of
ascorbic acid and 2mM b-glycerol phosphate). On formation of
ossified bone nodules, colonies are stained for alkaline
phosphatase activity and for Ca/PO4 deposition with von Kossa
stain. Progenitor cell number was assessed by counting the
number of ossification centers present [colony-forming units
osteoblast (CFU-Ob)]. No difference was seen in the number of
osteogenic centers at 3 weeks, but a 50% decrease in the number ofMAINTENANCE OF MESENCHYMAL PROGENITORS BY WNT10B Journal of Bone and Mineral Research 2143
Fig. 6. Wnt10b-null animals have reduced numbers of bone-derived
mesenchymal progenitors. Primary bone marrow stromal cells (PBMSCs)
were isolated from WT and Wnt10b-null animals at 1 (A, B) and 6 (C, D)
months of age, grown in Mesencult medium for 7 days, and stained with
Geimsa for enumeration of CFU-F. Similar cultures were switched to
osteogenic (E) or adipogenic ( F) medium to identify foci that could
differentiate into bone or fat cells.Wnt10b-null PBMSCs give rise to similar
numbers of CFU-F colonies compared with WT at 1 month of age (B) but
show a 40% reduction in the number of CFU-F colonies at 6 months (D).
Following expansion of WT PBMSCs in Mesencult, colonies were refed
with osteogenic differentiation medium and then costained for alkaline
phosphatase activity and calcium deposition (von Kossa) to identify
activation of the osteoblast program (E). Similar cultures were refed with
adipogenic medium and subsequently stained with oil red O to identify
activation of the adipogenic program (F). All experiments were per-
formed in triplicate. Technical replicates from a representative biologic
replicate are shown. All experiments in this figure use mice in the FVB
background. Statistical significance was evaluated by Student’s t test;
p< .05.osteogenic centers was found in cells isolated from bone marrow
stroma of Wnt10b-null animals at 6 months of age (Fig. 5D, E).
Next, we examined expression of osteogenic genes in PBMSCs
harvested from 6-month-old mice using quantitative RT-PCR
analysis of mRNA and found a 1.5-fold reduction in expression of
osteoblast differentiation markers alkaline phosphatase (ALP)
and osteocalcin (OCN) in Wnt10b mutants (Fig. 5G). Additionally,
we saw a 2-fold reduction in expression of the Wnt target gene
Id2 (Fig. 5G). No change was observed in the expression of Runx2
(Fig. 5G), an osteoblast associated transcription factor known to
be indispensable for osteoblast differentiation.(24–26)
Subsequently, we examined whether loss of Wnt10b expres-
sion affected only the osteogenic lineage or whether the
deficiency was at the level of a more primitive mesenchymal
progenitor with both osteogenic and adipogenic potential. Since
FVB mice are highly resistant to diet-induced weight gain, we
examined adipogenesis in PBMSCs isolated from 6-month-old
male C57/Bl6 mice using in vitro adipogenesis assays. PBMSCs
were isolated in Mesencult medium and induced to differentiate
down the adipogenic lineage by addition of GW1929, a small-
molecule agonist of peroxisomal proliferator-activated receptor-g
(PPARg). On formation of lipid droplets, cultures were stained with
oil redO for enumeration of colony-forming units adipocyte (CFU-A).
Similar to the results seen for osteogenesis in the FVB background, a
50% decrease in the number of adipogenic centers was found in
cells isolated from bone marrow stroma of C57/Bl6 Wnt10b-null
animals at 6 months compared with WT controls (Fig. 5F).
In order to determine if the observed decreases in colony
number were due to alterations in the proliferative capacity of
cells isolated from Wnt10b-null animals, we examined growth
rates of PBMSCs harvested from 6-month-old WT and Wnt10b-
null mice during expansion in growth medium and found no
difference in the rate of proliferation in vitro (Supplemental
Fig. 1B). We also examined proliferation in vivo in the
proliferative zone of the growth plate from postnatal day 4
mice. Immunohistochemistry to detect proliferating cell nuclear
antigen (PCNA), a marker of proliferation, reveals no difference in
the number of PCNAþ nuclei (Supplemental Fig. 1A).
Wnt10b-null animals have fewer mesenchymal
progenitors at 6 months
Since we were able to show a loss of progenitors that have
adipogenic and osteogenic potential in aged Wnt10b-null mice,
we were curious as to whether this resulted from a general loss of
mesenchymal progenitors in bone marrow–derived stromal
cells. Primary bone marrow stromal cells (PBMSCs) were isolated
from 1- and 6-month-old WT and Wnt10b-null animals and
grown in Mesencult medium. Mesencult is designed for
quantification of mesenchymal stem cells (MSCs) by the CFU-F
assay.(27) These assays showed no difference in the number of
CFU-F at 1 month of age (Fig. 6A, B) but revealed a 40% reduction
in CFU-F in Wnt10b-null PBMSCs (Fig. 6C, D) by 6 months.
In order to confirm that colonies isolated in Mesencult represent
multipotent mesenchymal progenitors, PBMSCs were allowed to
form colonies by isolation in Mesencult and then were switched to
either osteogenic or adipogenic medium and assessed for their
ability to differentiate into osteoblasts or adipocytes. Our results2144 Journal of Bone and Mineral Researchshow that the CFU-F isolated by growth in Mesencult were able to
differentiate down both osteogenic (Fig. 6E) and adipogenic
(Fig. 6F) pathways, confirming that these colonies represent a form
of multipotential mesenchymal progenitor.
MSCs in mice also can be analyzed by fluorescence micro-
fluorimetry (FACS) analysis, although the markers are not as well
developed for mouse MSCs as those for analysis of human MSCs.
Several lines of evidence suggest that cells with a surface marker
profile of lin–/Sca1þ/CD34–/CD44– or lin–/Sca1þ/CD34–/CD44þ
comprise a population of cells capable of giving rise to tissues of
the mesenchymal stem cell lineage.(28–30) We analyzed primary
bonemarrow isolates for both early (Lin–/Sca1þ/CD34–/CD44–) and
late MSCs (Lin–/Sca1þ/CD34–/CD44þ) from 2-, 3-, and 6-month-
old mice(31) (Supplemental Fig. 2). This analysis, though not as
definitive as the CFU assays, supports the notion that young
Wnt10b-null mice have fairly normal numbers of bone marrow–
derived MSCs but that the numbers of identifiable cells are
progressively reduced as the mice age.
Together these results provide support for the idea that
mesenchymal progenitor populations are reduced in Wnt10b-
null stroma, potentially indicating that mesenchymal progenitor
cells differentiate prematurely and thus are not maintained atWT
levels over the lifespan of the animal.STEVENS ET AL.
Discussion
Wnt signaling plays a major role in specification and growth of
bones, yet the individual ligands involved, as well as target cells
and mechanism, are poorly understood. Canonical Wnt signaling
has been shown to both stimulate self-renewal and repress
osteogenic differentiation of MSCs in vitro. Exogenous addition
of Wnt3a to ex vivo cell culture has been shown to inhibit
osteogenesis, as evidenced by decreased alkaline phosphatase
activity and expression, and to stimulate self-renewal and
expansion of immature osteoprogenitors in cultured human
MSCs (hMSCs).(10,11,32) Addition of canonical Wnt signaling antagonist
sFRP3 toWnt3a-treated osteogenic cultureswas sufficient to suppress
inhibition of differentiation and decrease proliferation.(10) Over-
expression of Wnt signaling coreceptor Lrp5 in hMSCs resulted in
increasedproliferation anddecreasedosteogenesis, an effect thatwas
enhanced in the presence of Wnt3a.(13) In a similar study, expression
of dominant-negative TCF4 or constitutively active b-catenin
resulted in increased proliferation and decreased differentiation
of hMSCs.(14) Together these studies suggest a role for canonical
Wnt signaling in inhibition of differentiation and maintenance of
immature pluripotent MSCs.
Here we show that Wnt10b-null mice have a progressive
osteopenia resulting from defects in postnatal bone home-
ostasis. Specifically, the loss of Wnt10b results in a defect in the
maintenance and/or self-renewal of mesenchymal progenitor
cells in bone marrow where the number of mesenchymal
progenitors is reduced over the life of the animal. Enhanced Wnt
signaling is a characteristic of several adult stem cell environ-
ments,(14) and loss of Wnt signaling results in loss of stem cell
maintenance in skin, bone marrow, and gut, among others.(33,34)
The identities of specific Wnt ligands that maintain distinct stem
cell populations are largely unknown.
Our results indicate that Wnt10b is one of the most important
ligands for maintenance of adult mesenchymal progenitor
activity that can be isolated from the bonemarrow stromal niche.
We demonstrate that both copies of Wnt10b are required for
normal maintenance of adult bone homeostasis and that the loss
of bone in aged heterozygous animals is as severe as that for
Wnt10b-null mice. Haploinsufficiency phenotypes for secreted
growth factors are rare, and this is the first report of haploinsuffi-
ciency in bone for a secreted Wnt ligand. Haploinsufficiency of Wnt
signaling pathway components GSK3b and Lef1 has been reported
previously to affect bone density preferentially in femalemice,(5) and
Lrp5 heterozygous mice show losses in bone mass that are not as
severe as those for Lrp5-null mice irrespective of gender.(35) Our
finding that loss of one allele of Wnt10b alone is sufficient to
affect bone homeostasis in male mice provides important new
information related to the importance ofWnt10b in normal adult
bone homeostasis.
Postnatal bone homeostasis is a delicate balance between
bone resorption by osteoclasts and bone deposition by
osteoblasts. We observed that osteoclast number and activity
are unaffected, indicating that bone resorption is not a major
contributor to the osteopenic defect. Interestingly, osteoblast
numbers also are unaffected in Wnt10b mutants. This result
indicates that the defect in bone homeostasis occurs in a more
primitive progenitor cell but that once the progenitors becomeMAINTENANCE OF MESENCHYMAL PROGENITORS BY WNT10Bosteoblasts, they posses normal properties in vivo. Several lines
of evidence support a role for Wnt10b in the maintenance of
bipotential mesenchymal progenitor cells. First, Wnt10b-null
mice have reduced bone volume fraction and trabecular number
at 2, 3, and 6months of age and fewer mesenchymal progenitors
at 6 months of age, as assessed by the CFU-F assay. Additionally,
Wnt10b-null mice form fewer osteogenic and adipogenic
colonies in in vitro CFU-Ob and CFU-A assays. The finding that
Wnt10b-null mice at 2 and 4 weeks of age show increased bone
volume fraction and trabecular number and equivalent numbers
of CFU-Ob and mesenchymal progenitors is suggestive of
accelerated differentiation into osteoblasts, leading to prema-
ture depletion of the pool of mesenchymal progenitor cells
available for bone deposition later in life. Taken together, these
data indicate a deficiency in maintenance or self-renewal of
mesenchymal progenitor cells that results in depletion of this
population as Wnt10b-null animals age. This interpretation is
very different from but not irreconcilable with the results
obtained by overexpression of Wnt10b from heterologous
promoters.(19,20)
A hallmark of stem cell self-renewal is an inhibition of
differentiation. We observed that Id2, a Wnt target gene,(36) is
expressed at lower levels in Wnt10b-null PBMSCs. At one level,
this result confirms that loss of Wnt10b expression is associated
with a subsequent reduction in a canonical Wnt target gene.
However, Id2 downregulation was examined because it could
explain, in part, the apparent enhanced osteogenic differentia-
tion in 1-month-old mice. Expression of Id2 has been shown
previously in a variety of progenitor cells. Downregulation of Id2
expression is critical for differentiation of lymphoprogenitor cells
toward a B-cell fate,(37) and Id2 expression also has been shown
to be important for adipogenesis.(38) One possibility is that
Wnt10b-responsive progenitors maintain pluripotency by main-
taining expression of inhibitors of differentiation. While the idea
that Wnt signaling contributes to the maintenance of immature
mesenchymal progenitor cells through induction of an anti-
differentiation program is intriguing, but further characterization
of this pathway in mesenchymal progenitors is needed. Lack of a
well-defined cell surface phenotype discriminating mesenchy-
mal progenitor andmesenchymal stem cells in the mouse makes
isolation and further characterization of the pathways mediating
maintenance of the progenitor pool difficult to accomplish
(reviewed in ref. (39)). Elucidation of the in vivo cell surface
phenotype of mesenchymal stem and progenitor cells will allow
for further examination of the role ofWnt10b in regulation of the
mesenchymal stem and progenitor cell niche in future studies.
By histomorphometry, we observed reductions in percent
mineralizing surface in 1-, 2-, and 6-month-old Wnt10b-null mice
and a decreased matrix apposition rate in 6-month-old animals.
Reductions in the extent of surface mineralization are consistent
with a reduction in mesenchymal/osteoprogenitor number.
However, the observed reduction in matrix apposition rate at
6 months does not allow us to rule out a role for Wnt10b in the
ability of osteoprogenitors to undergo osteogenesis. Studies
seeking to determine if Wnt10b plays a subsequent role in
differentiation of osteoprogenitors are currently under way.
Defects in bone development have been associated with
mutations in several components of the Wnt signaling pathwayJournal of Bone and Mineral Research 2145
(reviewed in refs. 6 and 7). In particular, Lrp5-null mice show a
loss of trabecular bone(35) similar to that in Wnt10b-null mice
described here. In both Lrp5-null and Wnt10b-null mice, the loss
of bone is not associated with alterations in Runx2 expression in
PBMSCs, suggesting that Wnt10b acts downstream of Runx2.
Runx2 is required for bone development and has long been
considered a key regulator of osteoblast differentiation.(24–26) In
contrast, we observed decreased expression of osteoblast
differentiation markers alkaline phosphatase and osteocalcin
in Wnt10b-null PBMSCs. These results could be indicative of
decreases in number or function of Runx2-expressing multi-
potential mesenchymal progenitor cells.
Overexpression of Wnt10b in mesenchymal progenitors
results in decreased adiposity in mice.(40) Interestingly, familial
mutations in the human WNT10B locus, resulting in a loss of
protein expression, implicate WNT10B as a potential factor in
human familial obesity.(41) Studies in our laboratory to determine
if adiposity is affected in Wnt10b-null mice have proved largely
unsuccessful. This could be due to the FVB background on which
these studies were created initially because FVB mice are highly
resistant to diet-induced weight gain.(42) However, backcrosses
of the line into C57 also have failed to reveal a pronounced
increase in adiposity. Therefore, additional studies will be
required to determine the effect of Wnt10b loss on adiposity in
mice. Additionally, participants in the human study carrying the
loss-of-function allele may have additional mesenchymal defects
in addition to body weight gain and should be assessed for
complications associated with osteopenia.
In conclusion we have demonstrated that loss of Wnt10b in
mice results in an age-progressive osteopenia and that loss of
one allele results in a fully penetrant osteopenic phenotype by
6 months of age. Additionally, the phenotype corresponds to an
age-dependent loss of multipotential mesenchymal progenitors
by 6 months of age. These results extend previous studies
showing a role for Wnt signaling in development and postnatal
bone homeostasis.(3,7,12,35,43–45) We have provided evidence that
Wnt10b is an endogenous Wnt ligand operating in bone and that
it functions to maintain mesenchymal and/or osteoblast
progenitors in adult bone. Recent identification of WNT10B
mutations in human pedigrees of severe obesity demonstrate
that altered activity at this locus contributes to additional defects
in mesenchymal derivatives. No other Wnt ligand has been
linked to mesenchymal progenitor function in both humans and
mice, making Wnt10b a critically important gene product for the
analysis of mesenchymal function.
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